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Abstract
Severe liver injury that occurs when immune cells mistakenly attack an individual’s own liver cells leads to autoimmune
hepatitis. In mice, acute hepatitis can be induced by concanavalin A (ConA) treatment, which causes rapid activation of
CD1d-positive natural killer (NK) T cells. These activated NKT cells produce large amounts of cytokines, which induce strong
inflammation that damages liver tissues. Here we show that PKC-h
2/2 mice were resistant to ConA-induced hepatitis due to
essential function of PKC-h in NKT cell development and activation. A dosage of ConA (25 mg/kg) that was lethal to wild-
type (WT) mice failed to induce death resulting from liver injury in PKC-h
2/2 mice. Correspondingly, ConA-induced
production of cytokines such as IFNc, IL-6, and TNFa, which mediate the inflammation responsible for liver injury, were
significantly lower in PKC-h
2/2 mice. Peripheral NKT cells had developmental defects at early stages in the thymus in PKC-
h
2/2 mice, and as a result their frequency and number were greatly reduced. Furthermore, PKC-h
2/2 bone marrow
adoptively transferred to WT mice displayed similar defects in NKT cell development, suggesting an intrinsic requirement for
PKC-h in NKT cell development. In addition, upon stimulation with NKT cell-specific lipid ligand, peripheral PKC-h
2/2 NKT
cells produced lower levels of inflammatory cytokines than that of WT NKT cells, suggesting that activation of NKT cells also
requires PKC-h. Our results suggest PKC-h is an essential molecule required for activation of NKT cell to induce hepatitis, and
thus, is a potential drug target for prevention of autoimmune hepatitis.
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Introduction
Mistaken attack of healthy liver cells by an individual’s own
immune system causes severe liver damage, leading to autoim-
mune hepatitis (AIH) [1]. A widely used murine AIH model is that
caused by concanavalin A (ConA) treatment, which rapidly
induces severe immune-mediated hepatitis due to activation of a
specific population of T cells, natural killer (NK) T cells, that are
enriched in liver [2]. Activated NKT cells produce large amounts
of inflammatory cytokines such as IFNc, IL-4, TNFa and MCP1,
which in turn recruit innate immune cells such as macrophages to
cause inflammatory responses [3,4]. In addition, activated NKT
cells also up-regulate FasL and induce hepatocyte apoptosis
through the FasL-Fas pathway. Fas/FasL-mediated apoptosis
appears to be an important mechanism for liver damage, as NKT
cells from Fas-mutant gld/gld mice fail to induce hepatitis [5,6].
Although ConA can activate other T cells, NKT cells are required
and sufficient for induction of liver damage in this murine AIH
model [7]. NKT cells are also thought to be involved in liver injury
induced by LPS, a-galactosylceramide (a-GalCer), Salmonella
infection, chronic hepatitis C infection and primary biliary
cirrhosis [8,9,10,11,12]. TCR signaling molecules are likely to
have an essential role in the activation of NKT cells responsible for
hepatitis, as suggested by the prevention of hepatitis by
immunosuppressive drugs such as FK506 or cyclosporine, which
inhibit conventional T cell receptor (TCR) signals [13]. Thus,
critical TCR signaling molecules are potential drug targets for
treatment of hepatitis; however, little is known about the signaling
molecules required for activation of NKT.
NKTcellsdevelopinthethymusandarepositivelyselectedbythe
MHC-I-like molecule CD1d [14], as indicated by complete absence
of NKT cells in CD1d-deficient mice [15]. NKT cell development
involves the following sequential stages: stage 0) CD24
hi; stage 1)
CD24
intCD44
negNK1.1
neg; stage 2) CD44
+NK1.1
2 and; stage 3)
CD44
+NK1.1
+ mature NKT cells [15]. Mature NKT cells express
TCRs that consist of an invariant Va14-Ja18 TCRab chain paired
with a limited number of TCRb chains, Vb8, Vb7o rV b2, which is
why they are called invariant NKT (iNKT). TCRs on NKT cells
recognize CD1d-presented glycolipids such as a-GalCer, a potent
activator of both mouse and human NKT cells [16]. Little is known
about the signaling pathways that regulate NKT development;
however, the NF-kB pathway is likely important, as a dominant
negative IkB transgene can arrest NKT development at the
CD44
+NK1.1
2 stage [17]. NF-kB is an important downstream
signaling molecule of TCR, and therefore is likely that TCR
mediates the activation of NF-kB required for NKT development.
PKC-h mediates the critical TCR signals required for
conventional T cell activation [18,19,20]. Engagement of TCR
induces activation of phospholipase Cc1 (PLCc1), which catalyzes
the hydrolysis of inositol phospholipids to produce diacylglycerol
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7(DAG) and inositol triphosphate (IP3). DAG activates PKCs [21].
Although phorbal esters activate multiple isoforms of PKC, PKC-
h is selectively required for T cell activation in vivo [19,20]. Mature
PKC-h
2/2 T cells failed to proliferate and produce interleukin 2
(IL-2) upon TCR stimulation due to defective activation of NF-kB
and AP1, and these observations are supported by several in vitro
studies in Jurkat T cells [22,23,24,25]. Mice deficient in other
isoforms of PKC do not display defects similar to those observed in
PKC-h
2/2 T cells [26], demonstrating the selective requirement of
PKC-h in T cell activation. Although many T cell-dependent
immune disease models have been used to demonstrate PKC-h
regulated T cells function in vivo [27], it is unknown how PKC-h
functions in NKT cell-mediated in vivo immune responses. In this
study, we used ConA-induced hepatitis to define the essential
function of PKC-h in NKT cell-mediated liver injury, strongly
suggesting PKC-h is a potential drug target for the prevention
autoimmune hepatitis.
Materials and Methods
Mice
All experiments involving mice were approved by the City of
Hope Institutional Animal Care and Use Committee. B6-Ly5.2/
Cr(CD45.1) mice were purchased from NCI laboratories (Freder-
ick, MD). PKC-h
2/2 mice were generated as previously described
[20]. Mice used were in C57BL/6 background and age/sex
matched between WT and PKC-h
2/2 mice. All mice were
maintained under specific pathogen-free conditions.
Antibodies and tetramers
Monoclonal antibodies CD3 (clone 145-2c11), NK1.1 (clone
PK136), CD44 (clone IM7), CD24 (clone M1/69), CD45.1 (clone
A20), CD45.2 (clone 104), IL4 (clone 11B11), INFc (clone
XMG1.2), FasL (clone MFL3) were purchased from eBioscience
(San Diego, CA). CD40L(clone MR1), Trail (clone N2B2) and
DR5 (clone MD5-1) were purchased from Biolegend (San Diego,
CA). The PE-CD1d-PBS157 tetramer was provided by the
tetramer core facility at the National Institutes of Health.
ConA and OCH treatment
ConA (Sigma, St. Louis, MO) was dissolved in pyrogen-free
phosphate-buffered saline (PBS), and intravenously injected
(25 mg/kg) into wild-type (WT) and PKC-h
2/2 mice via the tail
vein. Mouse survival was monitored for 56 h after injection. OCH
(provided by the National Institutes of Health), a specific antigen of
NKT cells, was injected intravenously (1 mg/mouse) via the tail vein
into both WT and PKC-h
2/2 mice. One hour after injection, mice
were bled and their sera collected. Mice were then sacrificed for
collection of intrahepatic lymphocytes as previously described [28].
Serum cytokine and ALT/AST assay
Collected sera were 1:10 diluted with the diluents provided by
the mouse inflammation CBA kit (BD Biosciences, San Diego,
CA). Inflammatory cytokines (INFc, TNF, MCP1, IL6) were
measured using the mouse inflammation CBA kit. Mouse IL-4 was
assayed with the flex set of cytokine assay beads (BD Biosciences).
Mouse serum ALT and AST were assayed with the enzymatic
assay kit (Bioo Scientific, Austin, TX). Mouse serum Osteopontin
(OPN) were assayed with Osteipontin mouse ELISA Kit (Abcam,
Cambridge, MA).
Surface and intracellular staining
Cells were incubated (30 min, 4uC, in the dark) with antibody
cocktail in staining buffer (2% FBS plus 0.1% sodium azide). Cell
samples were then washed and examined by BD FACSCanto II
(BD Biosciences). For intracellular staining, subsequent to surface
staining, cells were fixed with BD Cyto fix/perm buffer for 15 min
followed by two washes with Cyto perm/wash buffer. Cells were
then incubated (20 min, 4uC, in the dark) with IL-4/INFc cocktail
in Cyto/perm buffer. After two washes, cells were examined by
FACSCanto II. The FACS data were analyzed with Flowjo 7.4.6
(Tree Star).
Generation of bone marrow chimeric mice
Bone marrow (BM) transfer was performed as described [29].
Briefly, WT and PKC-h
2/2 mice received whole body c-
irradiation (two doses of 550 Rad given 3 h apart) with a cesium
source (Gammacell 40), and the bone marrow recipient mice were
reconstituted 6 h later with one intravenous injection of 5610
6
bone marrow cells from various adult donors. After 10 weeks of
reconstitution, mice thymus NKT cells were analyzed.
FACS sorting of NKT cells and in vitro stimulation
Pooled splenocytes and intrahepatic lymphocytes from batches
of two WT and two PKC-h
2/2 mice were stained with anti-CD3
antibody and CD1d-PBS157 tetramer as above, and the NKT
cells (CD3
lowCD1d-PBS157 tetramer
+ subset) sorted by BD
FACSAria III (BD Biosciences). The purified NKT cells were
cultured in 96 well plates (2.5610
5 cells/well) with 200 ml/well T
cell culture medium (RPMI 1640 supplemented with 10% fetal
calf serum, 5610
25 M 2-mercaptoethanol, 2 mM L-glutamine,
1 mM sodium pyruvate, 0.1 mM non-essential amino acids,
100 U/ml penicillin and 100 mg/ml streptomycin) with or without
100 ng/ml OCH as previously described [30]. After overnight
stimulation, cytokine levels in supernatants were assayed with BD
Flex set, and cells were harvested for IL4 and IFNc intracellular
staining as above.
Statistical analysis
Prism software (Graphpad) was used for all statistical analyses.
Unpaired students t tests were used to compare experimental
groups. A P value of less than 0.05 was considered statistically
significant.
Results
PKC-h
2/2 mice are resistant to ConA-induced hepatitis
To determine the function of PKC-h in liver injury, we used an
acute hepatitis murine model that depends on ConA-mediated
activation of NKT cells [31]. WT and PKC-h
2/2 mice, age and
sex matched, were treated with 25 mg/kg ConA, and their
survival rate was determined. Consistent with previous results [9],
this dosage of ConA was lethal for WT mice (Fig. 1A), whereas all
PKC-h
2/2 mice survived. Because damaged liver releases
aspartate transaminase (AST) and alanine transaminase (ALT),
we measured levels of both enzymes in serum of ConA-treated
mice to assess liver damage (Fig. 1B). Prior to ConA treatment,
AST and ALT levels were both very low (less than 50 U/L), and
there were no obvious differences between WT and PKC-h
2/2
mice (data not shown). After ConA treatment, although elevated,
AST and ALT levels of PKC-h
2/2 mice were significantly lower
than those of WT mice, suggesting there was less liver damage in
the absence of PKC-h. Because ConA treatment stimulates the
production of inflammatory cytokines that are critical mediators
for liver injury, we also measured serum cytokines after ConA
treatment. Levels of the inflammatory cytokines IL-6, IFNc and
monocyte chemotactic protein-1 (MCP1) were significantly lower
in PKC-h
2/2 than WT mice at 1 h (Fig. 1C), 2 h (Fig. 1D) and 6 h
PKCtheta in Hepatitis
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after stimulation in WT mice, which is consistent with published
results [32]. However, there was no such peak of TNFa detected
in PKC-h
2/2 mice. We also checked the serum levels of OPN,
which has important role in the hepatic inflammation and toxicity
[33], after challenged with ConA at different time point (Fig. 1F).
PKC-h
2/2 mice had lower levels of OPN in the early stage after
ConA challenge (1 h and 2 h). However, there was no obvious
difference in OPN levels between WT and PKC-h
2/2 mice 6 h
after ConA treatment, which is similar to TNFa. These results
suggest that PKC-h is required for ConA-induced inflammation
that is responsible for the liver injury.
PKC-h
2/2 mice have significantly fewer NKT cells
Since liver NKT cells are essential for ConA-induced hepatitis,
we examined NKT cell distributions in naı ¨ve WT and PKC-h
2/2
mice. Consistent with their role in liver injury [15], NKT cells
were enriched in liver tissues (28.9%) as compared to spleen
(1.23%) or bone marrow (0.21%) (Fig. 2A, left panel). The
percentage of NKT cells in liver (12.3%), spleen (0.342%) and
bone marrow (0.122%) of PKC-h
2/2 mice was always lower than
in WT mice (Fig. 2A, B). Furthermore, the absolute number of
NKT cells in spleen and liver were also significantly less in PKC-
h
2/2 mice (Fig. 2C), indicating that in the absence of PKC-h there
is a reduction in peripheral NKT cells, which are required for
ConA-induced hepatitis.
NKT cell development is defective in PKC-h
2/2 mice
That the number of peripheral NKT cells was reduced in all
PKC-h
2/2 tissues examined raised the possibility that NKT cell
development was inadequate. Since NKT cells develop in the
thymus, we assessed the thymic NKT cells. Consistent with results
for the periphery, significantly fewer NKT cells (percentage and
absolute number) were present in the thymi of PKC-h
2/2 mice
(Fig. 3A–D), suggesting abnormal NKT cell development. NKT
cell development can be divided into two major stages, stage 0 and
Figure 1. PKC-h
2/2 mice are resistant to ConA-induced hepatitis. PKC-h
2/2 mice and age and sex matched WT mice were challenged with a
lethal dosage of ConA (25 mg/kg). Survival was monitored every 3 h. N=7, from 2 independent experiments. A) Survival curve of mice challenged
with ConA. B) Serum ALT and AST levels 6 h after ConA challenge. C) Levels of the indicated cytokines in serum 1 h after ConA challenge. D) Levels of
the indicated cytokines in serum 2 h after ConA challenge. E) Levels of the indicated cytokines in serum 6 h after ConA challenge. F) Levels of serum
OPN different times after ConA challenge. (*, P,0.05; **, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0031174.g001
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The percentages of NKT cells in both stages were much lower in
PKC-h
2/2 mice (Fig. 3B), suggesting defective NKT development
at early stages. We further analyzed stage 1–3 cells with the surface
markers CD44 and NK1.1 (Fig. 3A, C). PKC-h
2/2 mice
accumulated significantly more cells at stages 1 and 2 (4.51%
and 14.2%, respectively) than did WT (3.94% and 6.68%),
suggesting a blockade at these two stages.
Since PLZF (promyelocytic leukemia zinc finger, Zbtb16) is
critical for NKT cell development and function [34], its
expression was thus detected by intracellular staining (Fig. 3E–
F). PLZF levels in PKC-h
2/2 NKT cells were not lower, actually
were slightly higher than WT NKT cells if there was any change,
suggesting that PLZF cannot explain the observed defective NKT
development in PKC-h
2/2 mice. In addition we examined levels
of CD1d which is required to present antigens for positive
selection of NKT cells in thymus [14]. No obvious differences in
CD1d expression were observed between WT and PKC-h
2/2
thymocytes (Fig. 3G), suggesting that defective NKT cell
development in PKC-h
2/2 mice is likely not due to abnormal
expression of CD1d. Taken together, our results strongly suggest
that PKC-h is required for NKT cell development in thymus,
which likely explains the reduction in peripheral NKT cells in
PKC-h
2/2 mice.
PKC-h is intrinsically required for NKT cell development
Intact PKC-h
2/2 mice lack PKC-h in all tissues. Therefore, to
determine whether defective NKT cell development is due to lack
of PKC-h in hematopoietic cells or the surrounding tissues, we
performed adoptive transfer to examine NKT cell development
arising from PKC-h
2/2 bone marrow in a WT environment. We
used an congenic marker, CD45.1 (donors) and CD45.2 (WT
recipients), to differentiate between donor and recipient cells, and
used four different adoptive transfer scenarios: WT (CD45.1) bone
marrow to WT (CD45.2) recipients (WTRWT), PKC-h
2/2 bone
marrow to WT (CD45.1) recipients (KORWT), WT (CD45.1)
bone marrow to PKC-h
2/2 recipients (WTRKO), and PKC-h
2/2
bone marrow to PKC-h
2/2 recipients (KORKO). Ten weeks after
bone marrow transfer, we examined thymic NKT cells (Fig. 4A
and left panel of C) and NKT cells at stages 0 and 1–3 (Fig. 4B and
right panel of C). Similar numbers of NKT cells developed from
WT bone marrow in WT or PKC-h
2/2 recipients, suggesting that
NKT cells can develop normally in a PKC-h
2/2 environment. In
contrast, PKC-h
2/2 bone marrow developed much fewer NKT
Figure 2. Reduced numbers of NKT cells in peripheral lymphoid tissues of PKC-h
2/2 mice. A) Flow cytometric analysis of CD1d-Tetramer-
positive and CD3-positive NKT cells mice in spleen (top panels), liver (middle panels) and bone marrow (bottom panels) of naı ¨ve WT (left panels) and
PKC-h
2/2 (right panels) mice. B) Frequency of NKT cells in organs described in A, as averaged from five mice of each genotype. C) Total NKT cell
number in spleen and liver as averaged from five mice of each genotype. (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0031174.g002
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2/2 recipients, demonstrating that
PKC-h
2/2 bone marrow failed to fully reconstitute the NKT cell
compartment, even in the WT environment (Fig. 4A, B). Thus,
these data show that PKC-h is intrinsically required for thymic
NKT cell development.
PKC-h
2/2 NKT cells are defective in production of
inflammatory cytokines
In response to activation, NKT cells produce cytokines that
mediate inflammatory responses to cause liver injury. We have
shown that PKC-h
2/2 mice produced lower levels of inflamma-
tory cytokines in response to ConA treatment (Fig. 1). However,
ConA can stimulate conventional T cells in addition to NKT
cells. Therefore, we examined cytokine production in response
to stimulation with OCH, a glycolipid ligand that binds to
CD1d and is specific for activation of NKT cells [15]. At 1 h
post OCH treatment, IL-6, MCP1, TNFa,I N F c and IL-4
levels in serum were all consistently much lower in PKC-h
2/2
mice (Fig. 5A). To specifically measure cytokines produced by
NKT cells, we performed intracellular staining of IFNc and IL-
Figure 4. Intrinsic requirement of PKC-h for NKT cell development. Bone marrow from WT and PKC-h
2/2 donors was adoptively transferred
to irradiated WT or PKC-h
2/2 recipients (6 mice per group). Ten weeks after adoptive transfer, NKT cells in thymi were analyzed by flow cytometry. A)
CD1d and CD3 NKT cells in thymi of adoptively transferred mice. B) Stage 0 and stage 1–3 NKT cells in thymi of adoptively transferred mice. C)
Frequencies of total NKT (left panel), and stage 0 and stage 1–3 NKT cells (right panel) as averaged from 6 recipients of each type of adoptive transfer.
(**, P,0.01).
doi:10.1371/journal.pone.0031174.g004
Figure 3. NKT cell development is defective in PKC-h
2/2 mice. A) Flow cytometric analysis of thymic NKT cells in WT (top panels) and PKC-h
2/2
(bottom panels) mice. Overall CD1d- and CD3-positive NKT cells in thymus were first analyzed (left panels), and the NKT cells were then divided into
stage 0 and stage 1–3 based on expression of CD24 (middle panels). Gated Stage 1–3 cells were further analyzed based on CD44 and NK1.1
expression to indicate each of the three stages (right panels). B) Frequency of NKT cells in thymus, stage 0 and stage 1–3 described in A, as averaged
from three mice of each genotype. C) Frequency of NKT cells at stages 1, 2 and 3 described in A, as averaged from three mice of each genotype. D)
Total NKT cell number in thymus as well as stage 0 and stage 1–3, as averaged from three mice (*, P,0.05; **, P,0.01; ***, P,0.001). E) FACS analysis
of PLZF expression in thymic NKT cells. PLZF expression in WT and PKC-h
2/2 NKT cells was analyzed using flow cytometry. F) GeoMean of PLZF
expression averaged from 3 independent experiments described in E. G) Lack of PKC-h does not affect surface CD1d levels on thymocytes. Histogram
of CD1d levels of WT (black line) and PKC-h
2/2 (dotted line) thymocytes.
doi:10.1371/journal.pone.0031174.g003
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Intrahepatic lymphocytes were collected based on the method
previously described [28]. Indeed, PKC-h
2/2 NKT cells
had reproducible reduced levels of both IFNc (Fig. 5B left
panel and Fig. 5C) and IL-4 (Fig. 5B right panel and Fig. 5C).
Consistently, IFNc and IL-4 production was also lower in
OCH-stimulated purified PKC-h
2/2 NKT cells compared to the
WT cells (Fig. 5D). These results thus suggest that PKC-h is
required to activate NKT cells to produce inflammatory
cytokines.
PKC-h
2/2 NKT up-regulate FasL, TRAIL and CD40L
normally
Upon activation, NKT cells up-regulate FasL, TRAIL and
CD40L, which contributes to ConA-induced hepatitis by
induction apoptosis [5,6,35,36]. Therefore, we examined their
expression after ConA stimulation (Fig. 6). There were no
obvious difference in FasL (Fig. 6A), Trail (Fig. 6B) and CD40L
(Fig. 6C) levels on NKT cells between WT and PKC-h
2/2 mice
before (left panels) or after (right panels) ConA challenge,
although stimulation up-regulated their levels as expected. In
addition, examination of expression of DR5 (Fig. 6D), the ligand
for Trail, on hepatocytes were found no difference between WT
and PKC-h
2/2 mice. These results suggest that it is unlikely that
FasL, Trail and CD40L contribute to the hepatitis-resistance
exhibited by PKC-h
2/2 mice.
Discussion
Liver diseases, including acute liver failure, viral hepatitis,
alcoholic liver disease, biliary cirrhosis and AIH, are serious
threats to public health. Although NKT cells represent only about
0.5% of total thymocytes and peripheral T cells, they comprise up
to 30% of the T cells in liver and play a critical role in liver
diseases [37]. Overwhelming activation of NKT cells, such as that
induced by ConA, a-GalCer, LPS and salmonella infection, causes
much damage, including severe injury of the liver [4,9,15]. ConA-
induced hepatitis has been used as a model for NKT-mediated
liver injury, which is closely resembles the pathology of human
AIH [4]. Inhibition of NKT cell activation is thus beneficial under
such circumstances. We found that PKC-h is a critical molecule
required for NKT cell activation by ConA and its lipid ligand, and
that deletion of PKC-h likely impairs liver injury in AIH. Many
highly specific PKC-h inhibitors have been developed by
pharmaceutical companies [38,39], and these inhibitors likely
have therapeutic value in the treatment of AIH.
Lack of PKC-h interferes with multiple NKT cell functions that
contribute to the ameliorated ConA-induced hepatitis observed in
PKC-h
2/2 mice. First, both the percentage of NKT cells and their
absolute number were reduced in liver. This reduction in NKT
cells is not restricted to liver, as reduced numbers of NKT cells
were also observed in the spleen, bone marrow and thymus. That
numbers of thymic NKT cells were significantly reduced suggests
Figure 5. NKT cells require PKC-h in order to produce cytokines. A) WT (black bars) and PKC-h
2/2 (open bars) mice were challenged with OCH
(1 mg) for 1 h, indicated cytokine levels in serum were detected (*, P,0.05; **, P,0.01). B. Mice were challenged with OCH (1 mg) for 1 h, IFNc(left
panel) and IL-4 (left panel) in WT (solid line) and PKC-h
2/2 (dotted line) NKT cells were detected by intracellular staining of intrahepatic lymphocytes.
Shaded area is isotype (ISO) antibody control. C) Intracelluar IFNc and IL-4 levels in NKT cells described in B are indicated by GeoMean obtained from
at least three independent experiments. D) Sorted NKT cells (CD3
LowCD1d-PBS57
+) were stimulated with 100 ng/ml OCH in vitro for overnight, and
IFNc and IL-4 levels in supernatant were measured (*, P,0.05; **, P,0.01).
doi:10.1371/journal.pone.0031174.g005
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confirmed by other observations [40,41]. However, it was not
clear at which stages NKT cell development was blocked. Our
results demonstrated a significant reduction in NKT cells starting
from the earliest developmental stages (stage 0), suggesting PKC-h
has a critical function during early NKT development. Further
analysis of stages 1–3 showed that lack of PKC-h lead to block
NKT cell development at stages 1 and 2 but not so much at stage
3, suggesting that PKC-h-mediated function is more important for
stage 1 and 2 NKT cell development than that of stage 3. We have
shown previously that PKC-h regulates NF-kB activation [20],
and NF-kB is apparently required for NKT development [17].
However, deletion of NF-kBp50 arrested NKT cell development
at stage 2, which is a later stage than what we observed in PKC-h
2/
2 mice. In addition to the NF-kB pathway, we and others have
shown that PKC-h also regulates signaling pathways such as AP1
and NFAT [42]. It is likely that PKC-h-regulated AP1 or NFAT
or both may play a role in early stages of NKT cell development.
The critical role of PKC-h in NKT development is in contrast to
conventional T cells, in which development is largely independent
of PKC-h [20], and it remains to be determined why PKC-h is
specifically required for the development of NKT cells.
In addition to reduced NKT cell number, defective NKT cell
activation also contributes to ameliorated hepatitis in PKC-h
2/2
mice. Inflammatory cytokines such as IFNc, IL-4 and TNFa that
are produced by activated NKT cells are essential mediators for
induction of hepatitis [4,17,31]. We found that NKT cells activated
by OCH in the absence of PKC-h produced much less IFNc, IL-4
and TNFa. Consistent with this, fewer NKT cells from PKC-h
2/2
mice produced IFNc and IL-4 in vitro and in vivo, suggesting that
reduced total number of NKT cells likely contributes to the reduced
serum TNFa. Interestingly, upon ConA treatment, TNFa, which
was lower in PKC-h
2/2 mice 1 hr after stimulation, but has no
obvious difference 2 hr and 6 hr after stimulation. It is important to
emphasize here that other cells such as macrophages also produce
TNFa upon activation. Therefore, it is possible that TNFa
produced by other cells may contribute to the increased TNFa
levels in serum. It appears that IL-4 can regulate TNFa production
in ConA-induced hepatitis, as exogenous IL-4 can boost TNFa
levels [43]. Therefore, the reduced IL-4 production by PKC-h
2/2
NKT cells may also be responsible for lower levels of TNFa in the
serum. Here we have demonstrated that PKC-h mediates signals
required for IFNc and IL-4 production by NKT cells, which
complements our previous results showing that PKC-c mediates
critical TCR signals required for IL-2 production in T cells [20]. In
addition to IFNc and IL-4, osteopontin produced by activated
NKT also contributes to ConA-induced hepatitis, indicated by the
resistance to ConA-induced hepatitis by osteopontin-deficient mice
[44]. Since PKC-h
2/2 mice have reduced NKT cell number and
impaired NKT cell activation, it is likely that osteopontin produced
by activated NKT cells is also correspondingly reduced in the
absence of PKC-h, which contributes to the observed impaired
hepatitis in PKC-h
2/2 mice.
Another potential mechanism responsible for NKT cell-induced
liver injury is FasL-induced hepatocyte apoptosis [5,6,35,36].
Similar to conventional T cells, activation of NKT cells leads to
up-regulation of FasL, which interacts with Fas on surface of
hepatocytes and induces apoptosis. The Fas-FasL-mediated
apoptosis is essential for ConA-induced hepatitis, as mutations in
this apoptotic pathway prevent hepatitis [5,6]. We have previously
shown that PKC-h is required for up-regulation of FasL in
conventional T cells and Fas/FasL-mediated activation-induced
cell death [45]. To our surprise, FasL was normally up-regulated
in NKT cells in the absence of PKC-h. Similarly, we also did not
find obvious difference in TRAIL, CD40, expression between WT
and PKC-h
2/2 NKT cells. CD40 expression on hepatocytes is also
not affected by deletion of PKC-h (data not shown). Therefore, in
contrast to other functions such as activation and cytokine
production, PKC-h plays a different function in conventional T
than in NKT cells during FasL and likely TRAIL and CD40 up-
regulation.
In summary, PKC-h
2/2 mice are resistant to ConA-induced
hepatitis, and this resistance is due to at least following mechanisms:
1) reduced NKT cell number due to an intrinsic requirement of
PKC-h for NKT cell development, and 2) reduced levels of
inflammatory cytokines such as IFNc and IL-4, because PKC-h
mediates the critical signals required for NKT activation. AIH in
humans is generally thought to be an immune disease. Similar to
many other autoimmunity, women are affected more than men
(gender ratio, 3.6:1) [46]. Immunosuppressive corticosteroid
treatment of AIH is effective [47]; however, corticosteroids have
broad effects on many tissues and have potential serious side effects
such as bone and skin problems as well as high blood pressure.
Highly specific drugs that target T cells, including NKT cells, are
likely better candidates for preventing liver injury induced by AIH.
PKC-h is specifically expressed in hematopoietic cells, particularly
in T cells, and deletion of PKC-h specifically affects T cell function
[20]. Therefore, many pharmaceutical companies have developed
PKC-h inhibitors to treat T cell-mediated autoimmunity. Consis-
tent with this, our study strongly suggests that PKC-h is a valuable
drug target for treatment of AIH.
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